Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.85 TWD
−116.47 M TWD
167.65 M TWD
About BioGend Therapeutics Co., Ltd.
Sector
Website
Headquarters
Taipei
Founded
2016
ISIN
TW0006733009
FIGI
BBG00PDLB2R7
BioGend Therapeutics Co., Ltd. engages in the development of medical equipment to restore bone and joint functions. Its products include bioactive bone graft material, biphasic cartilage repair implant and biological aggregates. The company was founded on July 7, 2016 and is headquartered in Taipei, Taiwan.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 6733 is 37.75 TWD — it has decreased by −0.92% in the past 24 hours. Watch BioGend Therapeutics Co., Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange BioGend Therapeutics Co., Ltd. stocks are traded under the ticker 6733.
6733 stock has fallen by −3.94% compared to the previous week, the month change is a −17.93% fall, over the last year BioGend Therapeutics Co., Ltd. has showed a 4.28% increase.
We've gathered analysts' opinions on BioGend Therapeutics Co., Ltd. future price: according to them, 6733 price has a max estimate of 49.00 TWD and a min estimate of 49.00 TWD. Watch 6733 chart and read a more detailed BioGend Therapeutics Co., Ltd. stock forecast: see what analysts think of BioGend Therapeutics Co., Ltd. and suggest that you do with its stocks.
6733 reached its all-time high on Jul 9, 2020 with the price of 63.35 TWD, and its all-time low was 14.55 TWD and was reached on Mar 19, 2020. View more price dynamics on 6733 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
6733 stock is 2.67% volatile and has beta coefficient of 0.80. Track BioGend Therapeutics Co., Ltd. stock price on the chart and check out the list of the most volatile stocks — is BioGend Therapeutics Co., Ltd. there?
Today BioGend Therapeutics Co., Ltd. has the market capitalization of 4.69 B, it has decreased by −1.63% over the last week.
Yes, you can track BioGend Therapeutics Co., Ltd. financials in yearly and quarterly reports right on TradingView.
BioGend Therapeutics Co., Ltd. is going to release the next earnings report on Mar 3, 2026. Keep track of upcoming events with our Earnings Calendar.
6733 earnings for the last quarter are −0.09 TWD per share, whereas the estimation was −0.09 TWD resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.10 TWD per share. See more details about BioGend Therapeutics Co., Ltd. earnings.
BioGend Therapeutics Co., Ltd. revenue for the last quarter amounts to 58.00 M TWD, despite the estimated figure of 58.00 M TWD. In the next quarter, revenue is expected to reach 60.00 M TWD.
6733 net income for the last quarter is −6.87 M TWD, while the quarter before that showed −23.19 M TWD of net income which accounts for 70.37% change. Track more BioGend Therapeutics Co., Ltd. financial stats to get the full picture.
No, 6733 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2025, the company has 34 employees. See our rating of the largest employees — is BioGend Therapeutics Co., Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioGend Therapeutics Co., Ltd. EBITDA is −56.92 M TWD, and current EBITDA margin is −42.39%. See more stats in BioGend Therapeutics Co., Ltd. financial statements.
Like other stocks, 6733 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioGend Therapeutics Co., Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioGend Therapeutics Co., Ltd. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioGend Therapeutics Co., Ltd. stock shows the buy signal. See more of BioGend Therapeutics Co., Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.